Immunotherapy Showing High Response Rate in Rare Lymphoma Called ENKTL, Trial Reports
News
Treatment with CS1001, an investigational immunotherapy, shows promising anti-tumor activity against relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (ENKTL) a rare and aggressive type of non-Hodgkin’s lymphoma, early Phase 2 ... Read more